Compliance takeaways from FDA’s final ‘intended use’ rule
By 
Jaclyn Jaeger2021-09-07T19:08:00
The U.S. Food and Drug Administration’s “intended use” final rule reaffirms the agency’s wide latitude of discretion in establishing an off-label use case against pharmaceutical and medical device companies.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefFDA bans Red No. 3 dye after decades of concerns over possible health risks
The U.S. Food and Drug Administration announced Wednesday it has revoked authorization for color additive Red No. 3 from food, beverages, and drugs. Health concerns over dye have existed since it was banned from cosmetics in 1990 after it was found that large doses led to the development of cancer ...
-
ArticleDOJ makes good on corporate-friendly enforcement policy with Balt resolution
The ink was barely dry on the U.S. Department of Justice’s new corporate enforcement policy (CEP) when the agency announced it would not prosecute Balt SAS for alleged bribery violations.
-
ArticleThe dos and don’ts of responding to a World Bank integrity audit
The World Bank Group has updated its “Integrity Compliance Guidelines” for the first time in 15 years, and at a time when sanctions cases are on the rise. These developments combined should prompt companies to reassess their anti-corruption compliance practices.
More from Regulatory Policy
-
ArticleEurope’s groundbreaking crypto rules put at risk by delays in implementation
Europe may have taken the lead in attempting to regulate cryptoasset firms before any other major jurisdiction, but a year after the ground-breaking rules came into force, it does not necessarily follow that they are robust or that the industry they are meant to hold accountable is embracing them.
-
ArticleCompliance must focus on corruption as EU and U.K. seek to tackle rising risks
Corruption isn’t something that happens somewhere else, in other countries and committed by other people. Nowhere is corruption-proof, and new rules being introduced in the EU and the U.K. aim to focus compliance officers on the full gamut of risks in all jurisdictions and every sector.
-
ArticleEmployment law in the age of AI: Compliance considerations
Employment law in the age of AI is evolving faster than many companies can keep pace. As more states enact AI laws and as more case law piles on, chief compliance officers and in-house counsel must ensure that compliance policies and procedures evolve as AI legal and compliance risks evolve.